97205 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells Stomach, Intestines
ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
#2RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
#3NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
#4ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#5RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
#6BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS I-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER
#7ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#8Methods for Manipulating Phagocytosis Mediated by CD47
#9ANTI-CANCER ANTIBODIES, COMBINATION THERAPIES, AND USES THEREOF
#10ANTIBODIES AGAINST TIM3 AND USES THEREOF
#11DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#12ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
#13ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
#14FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
#15CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
#16ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#17USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT
#18BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICRENVIRONMENT
#19BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
#20ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF
#21PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
#22COMPOSITIONS AND METHODS FOR DETECTING AND TREATING GASTRIC CANCER
#23DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#24Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#25USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT
#26BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#27RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
#28BINDING MOLECULES THAT INHIBIT CANCER GROWTH
#29ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES
#30Glycan-Interacting Compounds and Methods of Use
#31COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
#32ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS
#33ANTIBODY OR FRAGMENT THEREOF, AND METHOD FOR USING SAME
#34ANTIBODIES AGAINST TIM3 AND USES THEREOF
#35METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#36DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#37DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#38MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER
#39COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
#40CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO
#41METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE
#42IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY
#43Glycan-Interacting Compounds and Methods of Use
#44ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
#45Antibodies against TIM3 and uses thereof
#46Antibodies and methods for making and using the same
#47ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#48VEGF/DLL4 BINDING AGENTS AND USES THEREOF
#49DRUG CONJUGATES COMPRISING ANTIBODIES AGAINST CLAUDIN 18.2
#50Peptides for use in immunotherapy against cancers
#51NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#52TREATMENT WITH ANTI-VEGF ANTIBODIES
#53NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
#54RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
#55NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
#56NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
#57IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE
#58Cleavable tetrazine used in bio-orthogonal drug activation
#59NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
#60NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
#61Recombinant fusion proteins targeting CD47 and PD-L1, preparation and use thereof
#62FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
#63ANTIBODIES AGAINST CD73 AND USES THEREOF
#64Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner
#65MODULATION OF STIMULATORY AND NON-STIMULATORY MYELOID CELLS
#66Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#67ANTI-GLYPICAN-1-IMMUNIZING ANTIGEN RECEPTOR
#68Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#69ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#70BINDING MEMBERS
#71Methods for Manipulating Phagocytosis Mediated by CD47
#72PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS
#73ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#74Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#75Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#76Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#77ANTIBODY
#78Claudin18.2 binding moieties and uses thereof
#79Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#80Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#81ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
#82Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#83BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#84USE OF TIM-3 ANTIBODY IN PREPARATION OF MEDICINES FOR TREATING TUMORS
#85Anti-mesothelin binding proteins
#86CONJUGATED ANTIBOIDES AGAINST LY75 FOR THE TREATMENT OF CANCER
#87Antibody constructs and methods of treating cancer
#88ANTI-RSPO3 ANTIBODIES AND METHODS OF USE
#89IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE
#90ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#91METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#92Peptides for use in immunotherapy against cancers
#93Peptides for use in immunotherapy against cancers
#94METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#95Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#96METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITIONS PREDOMINANT (GARP) AND FOR PROVIDING EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
#97ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
#98BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
#99Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#100ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
#101Methods for manipulating phagocytosis mediated by CD47
#102Monoclonal antibody anti-FGFR4
#103ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF
#104GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF
#105Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
#106Co-Therapy Comprising A Small Molecule CSF-1R Inhibitor And An Agonistic Antibody That Specifically Binds CD40 For The Treatment Of Cancer
#107Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
#108CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO
#109VEGF/DLL4 binding agents and uses thereof
#110DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#111Emodin for Use in Regulating Expression of Proteins Involved in Inflammation
#112ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#113TREATMENT WITH ANTI-VEGF ANTIBODIES
#114ANTI-OX40 ANTIBODIES AND METHODS OF USE
#115COMBINATION THERAPIES
#116ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#117METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#118Antibodies to human B7x for treatment of metastatic cancer
#119Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
#120Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate
#121Monoclonal antibodies against Claudin-18 for treatment of cancer
#122METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES
#123IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
#124CHIMERIC ANTIGEN RECEPTOR, NKG2D CAR-NK CELLS EXPRESSING THE CHIMERIC ANTIGEN RECEPTOR, AND PREPARATION AND APPLICATION THEREOF
#125COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-EGFR ANTIBODIES
#126Cancer stem cell-specific molecule
#127Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#128COLON DISEASE TARGETS AND USES THEREOF
#129Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
#130Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#131Immunoconjugates with an intracellularly-cleavable linkage
#132Anti-ErbB3 antibodies and uses thereof
#133Glycan-Interacting Compounds and Methods of Use
#134Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#135ANTI RSPO ANTIBODIES AND METHODS OF USE
#136Combination therapy comprising nivolumab and ipilimumab
#137Antibodies against TIM3 and uses thereof
#138PRL3 antibody
#139TREATMENT WITH ANTI-VEGF ANTIBODIES
#140Immunoconjugates with an intracellularly-cleavable linkage
#141Anti-HER2 biparatopic antibody-drug conjugates and methods of use
#142Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#143Cancer-cell-specific anti-TMEM-180 monoclonal antibody, anticancer drug, and cancer testing method
#144ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR
#145Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
#146COMBINATION OF AN ANTI-VEGFR-2 ANTIBODY AND AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCER
#147Endoglin Antibodies
#148Antibodies and methods for making and using the same
#149NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
#150Modulation of stimulatory and non-stimulatory myeloid cells
#151Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#152Peptides for use in immunotherapy against cancers
#153Emodin for Use in Gastrointestinal Cancer Therapy
#154METHODS OF TREATMENT
#155Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#156TREATMENT WITH ANTI-VEGF ANTIBODIES
#157RNA-CODED ANTIBODY
#158ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF
#159Re-directed immunotherapy
#160Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
#161ANTI-LGR5 ANTIBODIES AND USES THEREOF
#162Cleavable tetrazine used in bio-orthogonal drug activation
#163Methods for Manipulating Phagocytosis Mediated by CD47
#164Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
#165ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
#166Targeting CLPTM1L for treatment and prevention of cancer
#167COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS
#168Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#169Immunoconjugates with an intracellularly-cleavable linkage
#170EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF
#171Anti-TROP2 antibody-drug conjugate
#172ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#173Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
#174Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor
#175High-affinity anti-human folate receptor beta antibodies and methods of use
#176CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
#177NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
#178Multispecific fab fusion proteins and use thereof
#179Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#180Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate
#181Antibodies against CD73 and uses thereof
#182COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS
#183VEGF/DLL4 BINDING AGENTS AND USES THEREOF
#184Compositions and Methods for Diagnosing and Treating Cancer
#185BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#186BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
#187Anti-mesothelin binding proteins
#188Binding molecules specific for HER3 and uses thereof
#189RECOMBINANT LISTERIA VACCINE STRAINS AND METHODS OF USING THE SAME IN CANCER IMMUNOTHERAPY
#190THERAPEUTIC DRUG FOR MALIGNANT TUMORS
#191Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#192ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#193COMPOSITIONS AND METHODS FOR DETECTING AND TREATING GASTRIC CANCER
#194Antibodies specific for Trop-2 and their uses
#195RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
#196Anti-PD-L1 combinations for treating tumors
#197Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#198Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
#199Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
#200Antibodies against claudin 18.2 useful in cancer diagnosis
#201Immunoconjugates with an intracellularly-cleavable linkage
#202Binding molecules that inhibit cancer growth
#203ANTI RSPO ANTIBODIES AND METHODS OF USE
#204VEGF/DLL4 binding agents and uses thereof
#205Antibodies against TIM3 and uses thereof
#206GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
#207COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
#208Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#209Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#210Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#211COLON DISEASE TARGETS AND USES THEREOF
#212Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer
#213Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#214Anti-CK8 antibodies for use in the treatment of colorectal cancers
#215Composition for treating diabetes or diabesity comprising oxyntomodulin analog
#216Sialyl-di-Lewisas expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
#217Anti-glypican-1-immunizing antigen receptor
#218Anti-OX40 antibodies and methods of use
#219TREATMENT WITH ANTI-VEGF ANTIBODIES
#220Methods for enhancing anti-tumor antibody therapy
#221VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS
#222COMBINATION THERAPY FOR CANCER
#223Endoglin Antibodies
#224Antibody molecules to PD-L1 and methods of treating cancer
#225COMBINED USE OF IMMUNE ACTIVATORS
#226Cancer therapy using CLDN6 target-directed antibodies in vivo
#227ANTI-LAMP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES, AND USES THEREOF
#228Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
#229Antibodies reactive with B7-H3 and users thereof
#230Systems and methods for determining optimum patient-specific antibody dose for tumor targeting
#231Monoclonal antibodies against claudin-18 for treatment of cancer
#232Anti-EGFR antibodies and antibody drug conjugates
#233Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof
#234Drug conjugates comprising antibodies against claudin 18.2
#235Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof
#236Anti-TROP2 antibody-drug conjugate
#237Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
#238Methods for treatment of cancer with therapeutic combinations comprising PEG-IL-10
#239CRYPTOPHYCIN-BASED ANTIBODY-DRUG CONJUGATES WITH NOVEL SELF-IMMOLATIVE LINKERS
#240Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides
#241NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#242Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancer
#243COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS
#244Anti-ErbB3 antibodies and uses thereof
#245Anti-EGFR monoclonal antibody, methods of making, and uses thereof in the treatment of cancer
#246IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY
#247Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
#248Antibodies against TIM3 and uses thereof
#249PATIENT-SPECIFIC IMMUNOTHERAPY FOR TREATING HETEROGENEOUS TUMORS
#250Antigen-binding constructs that bind to and inhibit catalase and/or superoxide dismutase as well as pharmaceutical compositions containing them for tumor therapy
#251Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
#252Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
#253TEM8 antibodies and their use in treatment and detection of tumors
#254Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
#255Methods of treating conditions with antibodies that bind B7-H4
#256Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor
#257Genetic products differentially expressed in tumors and the use thereof
#258Isolated nucleic acid encoding an anti-IGF-1R antibody
#259Methods for manipulating phagocytosis mediated by CD47
#260ANTI-RSPO3 ANTIBODIES AND METHODS OF USE
#261Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
#262Platform for the identification of tumor-associated cancer/testes antigens
#263COMPOSITIONS AND METHODS FOR TREATING CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES
#264RSPO BINDING AGENTS AND USES THEREOF
#265Modulation of stimulatory and non-stimulatory myeloid cells
#266ANTI-TROP-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#267Methods Of Treatment
#268Immunoconjugates with an intracellularly-cleavable linkage
#269PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER
#270Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method
#271Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
#272Antibodies against CD73
#273GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF
#274Enhancing the therapeutic activity of immune checkpoint inhibitor
#275Single-chain variable fragment anti-CD133 antibodies and uses thereof
#276BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
#277Immunoconjugates with an intracellularly-cleavable linkage
#278Pyrrolobenzodiazepines and conjugates thereof
#279Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
#280Anti-LGR5 antibodies and uses thereof
#281Prophylaxis of colorectal and gastrointestinal cancer
#282COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
#283Methods and materials for treating cancer
#284Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#285COMBINATION THERAPIES
#286USES OF ANTI-HER3 ANTIBODIES FOR TREATING CANCER
#287METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER
#288NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF
#289Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
#290Antibodies for epidermal growth factor receptor 3 (HER3)
#291METHOD FOR MANUFACTURING TRANSGENIC PLANT PRODUCING IMMUNOGENIC COMPLEX PROTEINS AND IMMUNOGENIC COMPLEX PROTEINS OBTAINED THEREFROM
#292EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF
#293FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
#294Compositions comprising a combination of nivolumab and ipilimumab
#295Methods for cancer therapy using mutant light molecules with increased affinity to receptors
#296IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
#297ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF
#298Methods for treatment of gastric cancer
#299Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
#300ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS